dexelvucitabine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor. that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.   Wikipedia

Chemistry

  • SMILES: NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](CO)C=C2
  • InChIKey: HSBKFSPNDWWPSL-CAHLUQPWSA-N
  • Mol. Mass: 227.19
  • ALogP: -0.59
  • ChEMBL Molecule:
    dexelvucitabine  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

2(1h)-pyrimidinone, 4-amino-1-((2s,5r)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro- | 2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine | 2',3'-dideoxy-2',3'-didehydro-beta-d-5-fluorocytidine | 2',3'-dideoxy-2',3'-didehydro-beta-l-5-fluorocytidine | 4-amino-5-fluoro-1-((2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1h)-one | dexelvucitabine | dpc817 | dpc 817 | dpc-817 | incb-8721 | reverset | yz-817

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

HIV (Phase 2)

HIV Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue